These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9501043)

  • 1. A minimally replicative HIV-2 live-virus vaccine protects M. nemestrina from disease after HIV-2(287) challenge.
    Looney DJ; McClure J; Kent SJ; Radaelli A; Kraus G; Schmidt A; Steffy K; Greenberg P; Hu SL; Morton WR; Wong-Staal F
    Virology; 1998 Mar; 242(1):150-60. PubMed ID: 9501043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.
    Matano T; Kano M; Nakamura H; Takeda A; Nagai Y
    J Virol; 2001 Dec; 75(23):11891-6. PubMed ID: 11689672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model.
    Otten RA; Ellenberger DL; Adams DR; Fridlund CA; Jackson E; Pieniazek D; Rayfield MA
    J Infect Dis; 1999 Sep; 180(3):673-84. PubMed ID: 10438354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A molecular clone of simian-human immunodeficiency virus (DeltavpuSHIV(KU-1bMC33)) with a truncated, non-membrane-bound vpu results in rapid CD4(+) T cell loss and neuro-AIDS in pig-tailed macaques.
    McCormick-Davis C; Dalton SB; Hout DR; Singh DK; Berman NE; Yong C; Pinson DM; Foresman L; Stephens EB
    Virology; 2000 Jun; 272(1):112-26. PubMed ID: 10873754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of HIV persistence: implications for vaccines and therapy.
    Bremermann HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug; 9(5):459-83. PubMed ID: 7627623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
    Ensoli B; Cafaro A
    J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
    Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of long-term protective effects against heterologous challenge in SIVhu-infected macaques.
    Villinger F; Switzer WM; Parekh BS; Otten RA; Adams D; Shanmugam V; Bostik P; Mayne AE; Chikkala NF; McClure HM; Novembre F; Yao Q; Heneine W; Folks TM; Ansari AA
    Virology; 2000 Dec; 278(1):194-206. PubMed ID: 11112494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses.
    Reimann KA; Watson A; Dailey PJ; Lin W; Lord CI; Steenbeke TD; Parker RA; Axthelm MK; Karlsson GB
    Virology; 1999 Mar; 256(1):15-21. PubMed ID: 10087222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue.
    Murakami T; Eda Y; Nakasone T; Ami Y; Someya K; Yoshino N; Kaizu M; Izumi Y; Matsui H; Shinohara K; Yamamoto N; Honda M
    AIDS; 2009 Jul; 23(12):1485-94. PubMed ID: 19528788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variation in a human immunodeficiency virus type 2 live-virus Macaca nemestrina vaccine model.
    Radaelli A; Kraus G; Schmidt A; Badel P; McClure J; Hu SL; Morton W; De Giuli Morghen C; Wong-Staal F; Looney D
    J Virol; 1998 Oct; 72(10):7871-84. PubMed ID: 9733824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental vaccination against HIV-1 protects the chimpanzee against challenge with injections of infected lymphocytes].
    Girard M; Kieny MP; Barré-Sinoussi F; Nara P; Muchmore E; Fultz P
    Bull Acad Natl Med; 1992 Jun; 176(6):921-34; discussion 935. PubMed ID: 1464038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Derivation and characterization of a highly pathogenic isolate of human immunodeficiency virus type 2 that causes rapid CD4+ cell depletion in Macaca nemestrina.
    McClure J; Schmidt AM; Rey-Cuille MA; Bannink J; Misher L; Tsai CC; Anderson DM; Morton WR; Hu SL
    J Med Primatol; 2000 Aug; 29(3-4):114-26. PubMed ID: 11085573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques.
    Zhang YJ; Putkonen P; Albert J; Ohman P; Biberfeld G; Fenyö EM
    Virology; 1994 May; 200(2):583-9. PubMed ID: 7909969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic and intestinal immune responses to HIV-2287 infection in Macaca nemestrina.
    Kuller L; Schmidt A; Mack H; Durning M; Birkebak T; Reiner MT; Anderson DM; Morton WR; Agy MB
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1191-204. PubMed ID: 11522188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.